In the first interview of the series, Judd W. Moul, MD, provides an overview of the management of mHSPC and mCRPC including key considerations in the use of the androgen deprivation therapy leuprolide with or without novel hormone therapy or chemotherapy.
In this companion article, Judd W. Moul, MD, of Duke University Medical Center, shares expert insights into factors affecting treatment decisions in metastatic hormone-sensitive and castration-resistant prostate cancer.
In the second interview of the series, Brenda Heath, RN, examines special considerations in the preparation and administration of formulations of leuprolide acetate and leuprolide mesylate.
In this companion article, Brenda Heath, RN, reflects on practical considerations in the preparation and administration of formulations of leuprolide acetate and leuprolide mesylate.
In the third interview of the series, Benjamin H. Lowentritt, MD, FACS, reflects on financial and operational considerations in the use of leuprolide with emphasis on managing the cost burden, coding and reimbursement, and product inventory.
In the fourth interview of the series, Brenda Heath, RN, shares expert insights into key factors related to nurse training on leuprolide administration, inventory management of the drug, and patient support programs.
In this companion article, Brenda Heath, RN, discusses key challenges related to the use of leuprolide acetate and leuprolide mesylate from an organizational management perspective.
